Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation reported a non-operating expense due to a foreign exchange loss of 19 million yen for the first quarter of 2025. This loss was primarily attributed to the revaluation of the company’s foreign currency denominated assets and liabilities, reflecting the impact of currency fluctuations on its financial performance.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, specializing in the biotechnology industry. The company focuses on developing innovative therapeutic solutions, with a particular emphasis on genetic and molecular therapies.
Average Trading Volume: 1,943,101
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.62B
For detailed information about 4883 stock, go to TipRanks’ Stock Analysis page.